'低后悔'的说法被揭露为有缺陷—真正的去过渡率仍然未知

去过渡率未知

Authors
J. Cohn
Journal
Archives of Sexual Behavior
Year
2023

Summary

Low regret figures such as 0.3–0.6% are often quoted to show that detransition is rare. In this opinion piece, J. Cohn argues that the true rates are unknown. He sets four conditions for a sound study: long enough follow-up (published times to regret range from about 3 to over 10 years), few people lost along the way, clear definitions and suitable measures, and patients like today's, who are mostly teenage girls. None of the studies in a 2021 review of surgery regret followed at least 85% of people for 8 or more years. Studies reporting higher rates fail the same tests. It is a useful checklist for reading regret studies, but it offers argument, not new data. Some of its cut-offs are judgement calls, and the author works with SEGM (the Society for Evidence-Based Gender Medicine), which urges caution in youth gender medicine.

Key findings

  • Cohn认为,与性别相关的医学治疗后停止、去过渡和后悔的比率是未知的。他并不是说真实比率很高或很低。
  • 常被引用的0.3%至0.6%后悔率主要来自在旧的、更严格的规则下接受治疗的成年人,而不是如今的患者,如今的患者多在青少年时期才首次出现性别痛苦,且多为女性。
  • 已发表的后悔或去过渡所需时间很长:从去过渡者调查中的约3年,到荷兰数据中切除睾丸或卵巢后平均近11年,瑞典数据中的典型时间约为7.5至8年。
  • 按照谨慎的最短8年标准,在2021年一篇关于手术后悔的综述(Bustos及同事)中,没有一项研究既随访了至少85%的患者,又对所有人随访8年或更长。
  • 只统计仍在性别诊所就诊的人,或只调查仍认为自己是跨性别者的人,会漏掉后悔或去过渡的整个群体。在一项调查中,只有约四分之一的去过渡者告诉过他们的临床医生。
  • 报告更高比率的研究,例如美国军队数据中近30%在四年内停用激素,也达不到同样的标准。
  • Cohn的结论是,考虑医学过渡的人应当被告知后悔或去过渡的几率是未知的,作为知情同意的一部分。

Conclusion

The detransition rate is unknown. Existing studies claiming low regret or detransition rates (0.3-0.6%) are unreliable due to methodological flaws including: insufficient follow-up time (often shorter than observed median times to regret of 7.5-8 years), high loss to follow-up, inappropriate measurement instruments, and non-representative samples that differ from current patient populations. The frequently quoted extremely low rates are based on studies with adults who underwent extensive screening under older protocols, not the current adolescent-onset cohort with different characteristics. Until properly designed long-term studies are conducted with adequate follow-up duration, small loss to follow-up, appropriate definitions and measurement tools, and relevant samples, the true rates of discontinuation, detransition, and regret cannot be determined. This uncertainty should be communicated to patients and families as part of informed consent for gender-affirming medical interventions.